• In early April 2026, Oscar Health drew attention after CEO Mark Bertolini bought 1,000,000 shares for US$11.92 million and regulators finalized 2027 Medicare Advantage reimbursement increases that will add more than US$13.00 billion in payments across the industry.
• The combination of a rare insider purchase amid prior insider selling and policy-driven revenue tailwinds for managed-care players is prompting investors to reassess Oscar Health’s longer-term positioning and risk-reward profile.
• We’ll now examine how Bertolini’s US$11.92 million share purchase could influence Oscar Health’s existing investment narrative and future earnings expectations.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Oscar Health Investment Narrative Recap

To own Oscar Health, you need to believe its tech-first ACA and Medicare model can convert rapid membership and revenue growth into durable profitability while keeping medical costs in check. Right now, the key near term catalyst is execution against 2026 profitability targets, with the biggest risk being that underwriting results and medical loss ratios do not improve as planned. Bertolini’s share purchase and the 2027 Medicare Advantage rate decision support sentiment but do not remove that core earnings risk.

The most relevant recent announcement here is the company’s 2026 guidance, calling for US$18.7–US$19.0 billion in revenue and US$250–US$450 million in earnings from operations. Against that backdrop, the CEO’s US$11.92 million insider buy and Medicare Advantage reimbursement uplift are being read as incremental support for the existing turnaround plan, rather than a wholesale reset of expectations for Oscar’s path to profitability.

Yet even with stronger sentiment, investors still need to weigh the risk that persistently high medical loss ratios could...

Oscar Health's narrative projects $21.6 billion revenue and $649.6 million earnings by 2029. This requires 22.7% yearly revenue growth and a $1.1 billion earnings increase from -$443.2 million today.

Uncover how Oscar Health's forecasts yield a $15.40 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Oscar could reach about US$13.8 billion of revenue and roughly US$575 million of earnings by 2028, which is far more upbeat than views focused on regulatory and affordability risks that could slow ACA exchange growth. These new developments may push you to reconsider which camp you lean toward as expectations get updated.

Explore 20 other fair value estimates on Oscar Health - why the stock might be worth 21% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.